Literature DB >> 12605561

The therapeutic potential of leptin.

Joseph Proietto1, Anne W Thorburn.   

Abstract

Many studies have reported the difficulty most subjects have in maintaining weight loss. Leptin is a cytokine-like protein made in adipose tissue and is transported into the brain by the blood-brain barrier where it inhibits food intake by altering the expression of hypothalamic neurotransmitters. The discovery of leptin raised the hope that a natural compound had been found that could cause weight loss without adverse effects. However, the majority of obese people have high levels of circulating leptin and it is not surprising that clinical trials published so far have shown that leptin only works effectively to suppress food intake in subjects who are hyperphagic as a result of low leptin levels. Obesity secondary to leptin deficiency is rare, most being associated with leptin insensitivity. To overcome leptin insensitivity, higher leptin levels in the CNS may be required. However, there is evidence that the leptin transport mechanism is saturated at low plasma leptin concentrations, limiting the effectiveness of peripherally-administered hormone. It is concluded that for leptin to have therapeutic potential, it either needs to be modified or the transport system by which leptin enters the brain needs to be upregulated to allow leptin to enter the brain more easily. To achieve effective weight loss, it may also be necessary to overcome central leptin insensitivity by developing agents that act downstream of leptin action.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605561     DOI: 10.1517/13543784.12.3.373

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  9 in total

Review 1.  The endocrinology of food intake.

Authors:  Denovan P Begg; Stephen C Woods
Journal:  Nat Rev Endocrinol       Date:  2013-07-23       Impact factor: 43.330

2.  Region-specific diet-induced and leptin-induced cellular leptin resistance includes the ventral tegmental area in rats.

Authors:  M Matheny; A Shapiro; N Tümer; P J Scarpace
Journal:  Neuropharmacology       Date:  2010-11-05       Impact factor: 5.250

3.  Differential physiological responses to central leptin overexpression in male and female rats.

Authors:  I Côté; S M Green; H Z Toklu; D Morgan; C S Carter; N Tümer; P J Scarpace
Journal:  J Neuroendocrinol       Date:  2017-12       Impact factor: 3.627

Review 4.  Pharmacotherapy for obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; John J McNeil
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding.

Authors:  Alexandra Shapiro; Wei Mu; Carlos Roncal; Kit-Yan Cheng; Richard J Johnson; Philip J Scarpace
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-08-13       Impact factor: 3.619

6.  Central overexpression of leptin antagonist reduces wheel running and underscores importance of endogenous leptin receptor activity in energy homeostasis.

Authors:  Michael Matheny; Yi Zhang; Alexandra Shapiro; Nihal Tümer; Philip J Scarpace
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-09-02       Impact factor: 3.619

7.  A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells.

Authors:  Ruben Rene Gonzalez; Paul C Leavis
Journal:  Endocrine       Date:  2003-07       Impact factor: 3.633

Review 8.  Chronic Oxytocin Administration as a Treatment Against Impaired Leptin Signaling or Leptin Resistance in Obesity.

Authors:  Jordi Altirriba; Anne-Laure Poher; Françoise Rohner-Jeanrenaud
Journal:  Front Endocrinol (Lausanne)       Date:  2015-08-05       Impact factor: 5.555

9.  Centrally administered urocortin 2 decreases gorging on high-fat diet in both diet-induced obesity-prone and -resistant rats.

Authors:  P Cottone; V Sabino; T R Nagy; D V Coscina; B E Levin; E P Zorrilla
Journal:  Int J Obes (Lond)       Date:  2013-03-12       Impact factor: 5.095

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.